【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.1.3 Prognosis and Quality of Life 27
3.2 Symptoms 29
3.2.1 Hemophilia A and B 29
3.2.2 Inhibitors 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.2.1 Almost 50% of hemophilia patients are affected by hypertension 33
4.3 Global Trends 34
4.4 Epidemiological Forecast of Hemophilia (2012-2022) 36
4.4.1 Forecast Methodology 36
4.4.2 Sources Used 37
4.4.3 Sources Not Used 38
4.4.4 Forecast Assumptions and Methods 38
4.5 Epidemiology Forecast (2012-2022), Hemophilia A 43
4.5.1 Diagnosed Prevalent Cases of Hemophilia A 43
4.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 45
4.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 47
4.5.4 Age-Standardized Prevalence of Diagnosed Hemophilia A 48
4.6 Epidemiology Forecast (2012-2022), Hemophilia B 50
4.6.1 Diagnosed Prevalent Cases of Hemophilia B 50
4.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 52
4.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 54
4.6.4 Age-Standardized Prevalence of Diagnosed Hemophilia B 56
4.7 Epidemiology Forecast (2012-2022), Hemophilia A and B 57
4.7.1 Diagnosed Prevalent Cases of Hemophilia A and B 57
4.7.2 Diagnosed Prevalent Cases of Hemophilia A and B by Sex 59
4.8 Discussion 61
4.8.1 Conclusions on Epidemiological Trends 61
4.8.2 Limitations of the Analysis 62
4.8.3 Strengths of the Analysis 63
5 Disease Management 64
5.1 Treatment Overview 64
5.1.1 Hemophilia A and B Diagnosis 65
5.1.2 Hemophilia A and B Treatment 65
5.1.3 Inhibitors Diagnosis 67
5.1.4 Inhibitors Treatment 67
5.2 US 69
5.2.1 Clinical Practice 69
5.3 France 72
5.3.1 Clinical Practice 72
5.4 Germany 74
5.4.1 Clinical Practice 74
5.5 Italy 76
5.5.1 Clinical Practice 76
5.6 Spain 78
5.6.1 Clinical Practice 78
5.7 UK 80
5.7.1 Clinical Practice 80
5.8 Japan 82
5.8.1 Clinical Practice 82
5.9 Argentina 84
5.9.1 Clinical Practice 84
5.10 China 86
5.10.1 Clinical Practice 86
6 Competitive Assessment 88
6.1 Overview 88
6.2 Strategic Competitive Assessment 89
6.3 Product Profiles – Major Brands, Hemophilia A 93
6.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 93
6.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 98
6.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free) 103
6.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 107
6.4 Product Profiles – Hemophilia B 110
6.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 110
6.4.2 Rixubis (BAX-326) 115
6.5 Product Profiles – Hemophilia A and B with Inhibitors 120
6.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 120
7 Opportunity and Unmet Need 123
7.1 Overview 123
7.2 Opportunities Analysis 124
7.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 124
7.2.2 Lower-Cost Recombinant Replacement Therapies 125
7.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 126
7.2.4 More Convenient Drug Administration 126
7.2.5 Oral Formulation of Recombinant Replacement Therapies 127
7.3 Unmet Needs Gap Analysis 128
7.3.1 Long-Acting FVIII Replacement Therapies 128
7.3.2 Gene Therapy Treatments for Hemophilia A and B 128
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Clinical Trial Mapping 129
8.2.1 Clinical Trials by Country 129
8.3 Clinical Trials by Phase and Trial Status 130
8.4 Promising Drugs in Clinical Development – Hemophilia A 131
8.4.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein) 133
8.4.2 BAY 94-9027 (octocog alfa) 140
8.4.3 BAX-855 145
8.4.4 Novoeight (turoctocog alfa; NN7008) 150
8.4.5 N8-GP (NN7088) 155
8.4.6 CSL-627 (rFVIII-SC) 160
8.4.7 Hcl-rhFVIII 165
8.5 Promising Drugs in Clinical Development – Hemophilia B 170
8.5.1 Alprolix (rFIXFc) 172
8.5.2 CSL-654 (rIX-FP) 177
8.5.3 N9-GP (NN-7999) 182
8.5.4 IB1001 (trenacog alfa) 187
8.6 Promising Drugs in Clinical Development – Hemophilia A and B Patients with Inhibitors 192
8.6.1 BAX-817 (rFVIIa BI) 192
9 Current and Future Players 197
9.1 Overview 197
9.2 Trends in Corporate Strategy 199
9.3 Company Profiles 200
9.3.1 Baxter 200
9.3.2 Biogen Idec 204
9.3.3 Novo Nordisk 206
9.3.4 CSL Behring 209
9.3.5 Bayer 210
9.3.6 Pfizer 212
10 Market Outlook 214
10.1 Global Markets 214
10.1.1 Forecast 214
10.1.2 Drivers and Barriers – Global Issues 218
10.2 US 221
10.2.1 Forecast 221
10.2.2 Key Events 225
10.2.3 Drivers and Barriers 225
10.3 France 228
10.3.1 Forecast 228
10.3.2 Key Events 231
10.3.3 Drivers and Barriers 231
10.4 Germany 233
10.4.1 Forecast 233
10.4.2 Key Events 236
10.4.3 Drivers and Barriers 236
10.5 Italy 238
10.5.1 Forecast 238
10.5.2 Key Events 241
10.5.3 Drivers and Barriers 241
10.6 Spain 243
10.6.1 Forecast 243
10.6.2 Key Events 246
10.6.3 Drivers and Barriers 246
10.7 UK 248
10.7.1 Forecast 248
10.7.2 Key Events 251
10.7.3 Drivers and Barriers 251
10.8 Japan 254
10.8.1 Forecast 254
10.8.2 Key Events 257
10.8.3 Drivers and Barriers 257
10.9 Argentina 259
10.9.1 Forecast 259
10.9.2 Key Events 263
10.9.3 Drivers and Barriers 263
10.10 China 266
10.10.1 Forecast 266
10.10.2 Key Events 269
10.10.3 Drivers and Barriers 269
11 Appendix 271
11.1 Bibliography 271
11.2 Abbreviations 287
11.3 Methodology 290
11.4 Forecasting Methodology 290
11.4.1 Diagnosed Hemophilia Patients 291
11.4.2 Percent Drug-Treated Patients 291
11.4.3 Drugs Included in Each Therapeutic Class 291
11.4.4 Launch and Patent Expiry Dates 292
11.4.5 General Pricing Assumptions 293
11.4.6 Individual Drug Assumptions 294
11.4.7 Pricing of Pipeline Agents 298
11.5 Physicians and Specialists Included in this Study 299
11.6 About the Authors 301
11.6.1 Authors 301
11.6.2 Epidemiologists 302
11.6.3 Global Head of Healthcare 303
11.7 About GlobalData 304
11.8 Disclaimer 304
【レポート販売概要】
■ タイトル：血友病A及びB：世界市場（医薬品市場予測及び分析～2022）■ 英文：PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022
■ 発行日：2013年11月30日
■ 調査会社：GlobalData
■ 商品コード：GDATA403162999
■ 調査対象地域：グローバル
- 鬱血性心不全治療薬の世界市場2015-2019About Congestive Heart Failure Drugs Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs ar …
- 石油・ガス腐食防止の世界市場分析：タイプ別（コーティング、塗料、阻害剤）、ロケーション別（オンショア、オフショア）、セクター別（上流、中流、下流）、セグメント予測、2014-2025The global oil & gas corrosion protection market is expected to reach USD 12.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness significant growth over the forecast period owing to rising demand from the North America region. Corrosion protection products are widely consumed in various applications sectors such as upstream, midstream and dow …
- 通信顧客向け課金管理ソリューションの世界市場2015-2019Consumer Billing Management Consumer billing management modules enable effective handling of all tasks and processes of financial relations with customers. These modules simplify operation of customers' accounts and provide more flexibility in invoicing with the help of multiple payment models, methods, and channels. They also provide customized billing and invoice calculation and end-to-end servi …
- Skytron：市場シェア分析Skytron Market Share Analysis Summary GlobalData’s new report, “Skytron Market Share Analysis” provides in-depth information on Skytron’s market position in the operating room equipment market. The report also provides data and information on the overall competitive landscape within the operating room equipment market. The report is supplemented with global corporate-level profile with information …
- 世界の小型風力タービン市場The wind energy market has witnessed enormous growth in the past few years as countries around the globe started increasing their use of renewable energy resources. The exponential growth of the wind energy market is fueled by the depleting reserves of fossil fuels, declining cost of wind power generation and a growing sensitivity for the environment. Wind turbines are machines that have the abili …
- 摩擦攪拌接合（FSW）装置の世界市場2016-2020About Friction Stir Welding Friction stir welding is a technique to join two metals or metal alloys via a solid-state joining process. The process makes use of a third tool that joins the two surfaces. The process involves the generation of heat that softens the surface near the friction stir welding tool. The two pieces of metal are intermixed at the joint, and mechanical pressure is applied by t …
- ハースの世界市場予測（～2023年）：暖炉、ストーブ、インサート“Increasing demand for esthetic home decor among customers is expected to drive the hearth market” The hearth market is expected to be valued at USD 15.72 billion in 2018 and is expected to reach USD 19.01 billion by 2023, at a CAGR of 3.87% between 2018 and 2023. On the basis of volume, the market is expected to register a shipment of 7.5 million units by 2023, at a CAGR of 6.22% during the forec …
- 温度伝送器および温湿度発信器の世界市場動向・予測（～2022）The global temperature transmitter market is expected to reach USD 3.58 Billion by 2022, at a CAGR of 4.19% during the forecast period. The global humidity transmitter market is expected to reach USD 1.36 Billion by 2022, at a CAGR of 1.84% between 2016 and 2022. The growing automation across all process industries to optimize the resources and improve the cost, safety, and security is driving the …
- 世界のOils&Fats市場動向（2014年4月）：ニュース・イベントSynopsis Using this report, marketers will effectively gain an insight into the latest happenings in the global oils and fats market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global oils and fats market on a monthly basis. Scope The report provides a review of the latest news and key events in the g …
- マイクロ・モバイル・データセンターの世界市場2016-2020About Micro-Mobile Data Center A micro-mobile data center is a small self-contained system designed to be a single rack enclosure that houses IT infrastructure with additional support infrastructure such as power and cooling systems. These data centers can support IT load of around 10 kW and are suitable for branch office operations and edge computing purposes. Deploying a micro-mobile data center …
- 再狭窄：治療薬のグローバル治験動向（2014年下半期）Restenosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Restenosis Global Clinical Trials Review, H2, 2014" provides data on the Restenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Restenosis. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
- 高リン血症治療薬の世界市場：インサイト、市場機会、市場シェア、市場予測Hypophosphatemia predicted in patients who have an antiquity of starvation, anorexia/bulimia, alcoholism. Adequate cure comprises phosphate supplements along with feeding and care to causal eating disorders or substance exploitation. The global hypophosphatemia drugs market is driven by increasing aging population. According to WHO the world aged population by the end of 2050 is expected to reach …
- 電気手術の世界市場予測（～2021）：製品別（発電機、器具-バイポーラ（ベッセルシーリング、鉗子）＆モノポーラ（ペンシル、電極）、アクセサリ、アルゴン＆排煙管理システム）、手術種類別The electrosurgery market is expected to reach USD 5.17 Billion by 2021 from USD 4.27 Billion in 2016, at a CAGR of 3.9% between 2016 and 2021. Factors such as technological advancements in electrosurgery devices, growing number of medical, aesthetic and plastic surgeries, rising demand for minimally invasive surgeries, and growing number of ambulatory surgery centers are driving the growth of thi …
- ソフトドリンク市場：東ティモールThis report is a comprehensive research of soft drink industry in Timor-Leste. The first two chapters of the report feature the country profile by giving general information on Timor-Leste and by thoroughly studying its economic state, (including key macroeconomic indicators and their development trends). The third chapter covers common business procedures in the country: from starting a project t …
- Mitsubishi Corporation：石油・ガスの開発・生産動向及びコスト分析– 2012Mitsubishi Corporation Oil & Gas Exploration and Production Operations and Cost Analysis – 2012 Summary Mitsubishi Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
